help button home button Am J Pathol Epitomics, Inc.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dorfman, D. M.
Right arrow Articles by Shahsafaei, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dorfman, D. M.
Right arrow Articles by Shahsafaei, A.
(American Journal of Pathology. 2003;162:1539-1544.)
© 2003 American Society for Investigative Pathology

Loss of Expression of the WNT/ß-Catenin-Signaling Pathway Transcription Factors Lymphoid Enhancer Factor-1 (LEF-1) and T Cell Factor-1 (TCF-1) in a Subset of Peripheral T Cell Lymphomas

David M. Dorfman, Harvey A. Greisman and Aliakbar Shahsafaei

From the Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts

T cell factor-1 (TCF-1) and lymphoid enhancer factor-1 (LEF-1), members of the TCF/LEF family of transcription factors, play a significant role in T cell development and are expressed in thymocytes and peripheral CD3+ T cells. Previously, precursor T lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LyL) was found to express TCF-1, and we find that 9 of 10 cases of T-ALL/LyL express LEF-1 as well as TCF-1, exhibiting uniform nuclear immunostaining for both transcription factors. In addition, a significant subset of cases of peripheral T cell lymphoma (PTCL), 39 of 81 cases (48%), are immunoreactive for LEF-1 and/or TCF-1, with 36 of 38 cases immunoreactive for both, indicating that these transcription factors are coordinately expressed in PTCL. The vast majority of LEF-1+ and/or TCF-1+ PTCL (34 of 39 or 87%) exhibit a composite Th1 T-cell-like immunophenotype, based on expression of Th1 T cell-associated, but not Th2 T cell-associated, chemokine receptors and activation markers. Of the Th1-like PTCL studied, 33 of 42 (79%) were immunoreactive for LEF-1 and 32 of 42 (76%) were immunoreactive for TCF-1, including most cases of angioimmunoblastic lymphoma and all cases of lymphoepithelioid lymphoma. Surprisingly, none of the 21 cases of Th2-like PTCL studied, all cases of anaplastic large cell lymphoma, were immunoreactive for LEF-1 or TCF-1 (P < 0.0001), suggesting that LEF-1 and TCF-1 transcription factor expression may be lost in Th2 T cells or Th2-like PTCL. LEF-1 and TCF-1 immunostaining can serve to identify specific subtypes of PTCL, and lends support to a bipartite model of PTCL development, based on expression of activation markers.




This article has been cited by other articles:


Home page
 BloodHome page
M. C. Ghosh, G. D. Collins, B. Vandanmagsar, K. Patel, M. Brill, A. Carter, A. Lustig, K. G. Becker, W. W. Wood III, C. D. Emeche, et al.
Activation of Wnt5A signaling is required for CXC chemokine ligand 12-mediated T-cell migration
Blood, August 13, 2009; 114(7): 1366 - 1373.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. Hebenstreit, M. Giaisi, M. K. Treiber, X.-B. Zhang, H.-F. Mi, J. Horejs-Hoeck, K. G. Andersen, P. H. Krammer, A. Duschl, and M. Li-Weber
LEF-1 Negatively Controls Interleukin-4 Expression through a Proximal Promoter Regulatory Element
J. Biol. Chem., August 15, 2008; 283(33): 22490 - 22497.
[Abstract] [Full Text] [PDF]

Home page
 Exp Biol MedHome page
L. Jin, Y. Li, C.-J. Chen, M. A. Sherman, K. Le, and J. E. Shively
Direct Interaction of Tumor Suppressor CEACAM1 with Beta Catenin: Identification of Key Residues in the Long Cytoplasmic Domain
Exp Biol Med, July 1, 2008; 233(7): 849 - 859.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Shin, S. Monti, D. J. Aires, M. Duvic, T. Golub, D. A. Jones, and T. S. Kupper
Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome
Blood, October 15, 2007; 110(8): 3015 - 3027.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Bosco, K. L. McKenna, C. J. Devitt, M. J. Firth, P. D. Sly, and P. G. Holt
Identification of novel th2-associated genes in T memory responses to allergens.
J. Immunol., April 15, 2006; 176(8): 4766 - 4777.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C.-W. Lin, T.-Y. Liu, S.-U. Chen, K.-T. Wang, L. J. Medeiros, and S.-M. Hsu
CD94 1A transcripts characterize lymphoblastic lymphoma/leukemia of immature natural killer cell origin with distinct clinical features
Blood, November 15, 2005; 106(10): 3567 - 3574.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
Z. Lin, D. K. Crockett, S. D. Jenson, M. S. Lim, and K. S. J. Elenitoba-Johnson
Quantitative Proteomic and Transcriptional Analysis of the Response to the p38 Mitogen-activated Protein Kinase Inhibitor SB203580 in Transformed Follicular Lymphoma Cells
Mol. Cell. Proteomics, August 1, 2004; 3(8): 820 - 833.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Society for Investigative Pathology.